- $932.79m
- $789.86m
Brief: Savara Announces Encore Presentations Of Results From Phase 3 IMPALA-2 Clinical Trial Of Molgramostim Inhalation Solution
U.S. RESEARCH ROUNDUP-Apple, Sanofi, Watts Water Technologies
Brief: New England Journal Of Medicine To Publish Results From Savara’S Phase 3 Impala-2 Clinical Trial In Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc reports results for the quarter ended June 30 - Earnings Summary
Savara Inc expected to post a loss of 12 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE- AMC,Natgas companies,Hologic
U.S. STOCKS ON THE MOVE-BellRing, Coeur, AMC Entertainment
Savara plunges after FDA refuses to accept application for lung disease drug
Savara Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Savara Q1 Net Income USD -26.639 Million
Savara Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
Brief: Savara Inc - Terminates ATM Agreement With Evercore Effective April 2, 2025 - SEC Filing
Brief: Savara Q4 Net Income USD -29.044 Million
Brief: Savara Enters Into Non-Dilutive Debt Financing For Up To $200M With Hercules Capital
Brief: Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview